Free Trial
NYSE:RMD

ResMed (RMD) Stock Price, News & Analysis

ResMed logo
$243.78 +0.18 (+0.07%)
(As of 11/22/2024 ET)

About ResMed Stock (NYSE:RMD)

Key Stats

Today's Range
$241.44
$243.89
50-Day Range
$231.43
$256.07
52-Week Range
$151.95
$260.49
Volume
551,442 shs
Average Volume
1.12 million shs
Market Capitalization
$35.79 billion
P/E Ratio
32.29
Dividend Yield
0.87%
Price Target
$225.70
Consensus Rating
Moderate Buy

Company Overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

ResMed Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
96th Percentile Overall Score

RMD MarketRank™: 

ResMed scored higher than 96% of companies evaluated by MarketBeat, and ranked 53rd out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ResMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    ResMed has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about ResMed's stock forecast and price target.
  • Earnings Growth

    Earnings for ResMed are expected to grow by 8.30% in the coming year, from $9.28 to $10.05 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ResMed is 32.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.30.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ResMed is 32.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 92.85.

  • Price to Earnings Growth Ratio

    ResMed has a PEG Ratio of 1.77. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    ResMed has a P/B Ratio of 6.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about ResMed's valuation and earnings.
  • Percentage of Shares Shorted

    5.37% of the outstanding shares of ResMed have been sold short.
  • Short Interest Ratio / Days to Cover

    ResMed has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in ResMed has recently decreased by 8.89%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    ResMed has a dividend yield of 0.87%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    ResMed has been increasing its dividend for 13 years.

  • Dividend Coverage

    The dividend payout ratio of ResMed is 28.08%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, ResMed will have a dividend payout ratio of 21.09% next year. This indicates that ResMed will be able to sustain or increase its dividend.

  • Read more about ResMed's dividend.
  • Percentage of Shares Shorted

    5.37% of the outstanding shares of ResMed have been sold short.
  • Short Interest Ratio / Days to Cover

    ResMed has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in ResMed has recently decreased by 8.89%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    ResMed has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 27 news articles for ResMed this week, compared to 10 articles on an average week.
  • Search Interest

    8 people have searched for RMD on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added ResMed to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ResMed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,882,278.00 in company stock.

  • Percentage Held by Insiders

    Only 0.71% of the stock of ResMed is held by insiders.

  • Percentage Held by Institutions

    54.98% of the stock of ResMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ResMed's insider trading history.
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

RMD Stock News Headlines

Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
ResMed Inc Director Expands Stock Holdings
ResMed Inc Awards RSUs to Director Desney Tan
ResMed Director Acquires Shares, Signals Confidence
ResMed Inc Director Acquires Shares Through RSUs
See More Headlines

RMD Stock Analysis - Frequently Asked Questions

ResMed's stock was trading at $172.02 at the start of the year. Since then, RMD shares have increased by 41.7% and is now trading at $243.78.
View the best growth stocks for 2024 here
.

ResMed Inc. (NYSE:RMD) posted its quarterly earnings data on Thursday, October, 24th. The medical equipment provider reported $2.20 EPS for the quarter, beating analysts' consensus estimates of $2.03 by $0.17. The business's quarterly revenue was up 11.1% on a year-over-year basis.
Read the conference call transcript
.

ResMed subsidiaries include these companies: Propeller Health, and Matrixcare.

Top institutional investors of ResMed include State Street Corp (4.27%), Geode Capital Management LLC (2.63%), Charles Schwab Investment Management Inc. (0.63%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.51%). Insiders that own company stock include Michael J Farrell, Robert Andrew Douglas, Brett Sandercock, David Pendarvis, Peter C Farrell, Kaushik Ghoshal, Justin Leong, Michael J Rider, Karen Drexler, Lucile Blaise, Witte Jan De and James Hollingshead.
View institutional ownership trends
.

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ResMed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Ex-Dividend for 9/19 Dividend
8/15/2024
Dividend Payable
9/19/2024
Last Earnings
10/24/2024
Ex-Dividend for 12/12 Dividend
11/07/2024
Today
11/24/2024
Dividend Payable
12/12/2024
Next Earnings (Estimated)
1/22/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
76115210
Employees
9,980
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$225.70
High Stock Price Target
$283.00
Low Stock Price Target
$180.00
Potential Upside/Downside
-7.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$1.02 billion
Pretax Margin
28.62%

Debt

Sales & Book Value

Annual Sales
$4.69 billion
Cash Flow
$9.23 per share
Book Value
$35.39 per share

Miscellaneous

Free Float
145,754,000
Market Cap
$35.79 billion
Optionable
Optionable
Beta
0.69

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NYSE:RMD) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners